Telangana Drug Control officials today started "freezing" the company's blockbuster drug, Avastin, based on information that it received from its Gujarat counterparts saying that the drug has allegedly hampered vision for some patients who had usedit, a senior official of the Drug Control Administration the state said.
"We have received information that the drug caused some vision problems to patients in Gujarat. As a precautionary measure we started freezing the samples of Avastin. It is not made in India. It is imported into the country," MAmruth Rao, Deputy Directorof DCA, told PTI.
On January 14, the sales of drug were put on hold in Gujarat.
"We have asked the Switzerland-based drug manufacturing company H Hoffmann-La Roche Ltd and importer company in Mumbai Roche product (I) to put on hold the sale of Avastin injections of that batch number," Gujarat Food and Drug Control Administration(FDCA) Chairman H G Koshia said.
"We have not banned the drug yet but as the hospital authorities suspect that the problem came up after they were given Avastin injections, as a precautionary measure we have asked the company not to sell this batch of the drug in the market," he said.
Meanwhile, some of the 15 patients who complained of partial vision loss were operated upon by doctors on January 13 and 14.
These patients were undergoing treatment for various eye ailments at the civic-run C H Nagri Eye Hospital in Ahmedabad.
Commenting on the development, a Roche India spokesperson said: "Our carrying and forwarding agent in Hyderabad has received a communication to hold salesfor a period of 20 days. We have also received communication from the Deputy Commissioner, FDA Gujarat, requesting for supply details of a specific batch of Avastin and technical testing protocols."
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
